These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16472435)

  • 1. [High-density lipoprotein: a new target in the battle against atherothrombotic disease].
    Hansen PR
    Ugeskr Laeger; 2006 Jan; 168(5):468-70. PubMed ID: 16472435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    Tavintharan S; Lim SC; Sum CF
    Singapore Med J; 2005 Oct; 46(10):519-28. PubMed ID: 16172771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDL as a target in the treatment of atherosclerotic cardiovascular disease.
    Linsel-Nitschke P; Tall AR
    Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
    Forrester JS; Makkar R; Shah PK
    Circulation; 2005 Apr; 111(14):1847-54. PubMed ID: 15824213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
    Feeman WE
    Circulation; 2003 May; 107(20):e199. PubMed ID: 12777330
    [No Abstract]   [Full Text] [Related]  

  • 7. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease.
    Brewer HB
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):387-91. PubMed ID: 15003970
    [No Abstract]   [Full Text] [Related]  

  • 10. High-density lipoprotein cholesterol-raising strategies.
    Kuvin JT; Alsheikh-Ali AA; Karas RH
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):196-204. PubMed ID: 16495756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol.
    Nicholls S; Lundman P
    Semin Vasc Med; 2004 May; 4(2):187-95. PubMed ID: 15478040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein.
    Shah PK
    Am J Cardiol; 2007 Dec; 100(11 A):S62-7. PubMed ID: 18047855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model.
    Gaofu Q; Jun L; Xiuyun Z; Wentao L; Jie W; Jingjing L
    Life Sci; 2005 Oct; 77(21):2690-702. PubMed ID: 15963532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is raising HDL a futile strategy for atheroprotection?
    Joy T; Hegele RA
    Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL: still a target for new therapies?
    Nicholls SJ
    Curr Opin Investig Drugs; 2008 Sep; 9(9):950-6. PubMed ID: 18729001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-density lipoprotein cholesterol: ready for prime time?
    Kon YC
    Singapore Med J; 2005 Oct; 46(10):507-13. PubMed ID: 16172769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.